Email this page
Print
Bookmark and share
Bigger
Smaller
Download PDF
RSS feedFor consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
NPS RADAR November 2007NPS RADAR November 2007
NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.
Find out more about NPS RADAR.
| Title | Why read this |
|---|---|
| NPS RADAR November 2007 Professional publication - NPS RADAR - Complete issue | NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals. |
| Correspondence from Servier Laboratories on strontium ranelate Professional publication - NPS RADAR - Correspondence | Correspondence between Servier Laboratories and NPS on use of strontium ranelate for postmenopausal osteoporosis. |
| Strontium ranelate (Protos) for postmenopausal osteoporosis Professional publication - NPS RADAR - Review | Reviews use of strontium ranelate for postmenopausal osteoporosis, with emphasis on reducing risk of fracture. |
| Additional content — Strontium ranelate (Protos) for postmenopausal osteoporosis: Differences between trial populations used for indirect comparisons between strontium and alendronate Professional publication - NPS RADAR - Web only item | Comparison of TROPOS, SOTI, FIT-1, and FIT-2 trial populations provided as additional content on strontium ranelate (Protos) for postmenopausal osteoporosis. |
| Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus Professional publication - NPS RADAR - Review | Rosiglitazone improves glycaemic control but there is a lack of evidence that it improves diabetes–related clinical complications and mortality. Rosiglitazone is no longer indicated in combination with insulin or for triple oral therapy in combination with metformin and a sulfonylurea. Rosiglitazone is a third-line choice. It may still be considered as part of dual therapy when either metformin or a sulfonylurea is contraindicated or not tolerated. Insulin should also be considered instead of rosiglitazone in these scenarios. Do not use rosiglitazone in people with heart failure or a history of heart failure. |
| Intolerance and contraindications to metformin Professional publication - NPS RADAR - Web only item | Lists adverse effects of and contraindications to metformin, including gastrointestinal symptoms, lactic acidodis, and renal impairment. |
| New York Heart Association grading of heart failure (NYHA) Professional publication - NPS RADAR - Web only item | Provides New York Heart Association grading of heart failure (NYHA) as additional content to rosiglitazone use for type 2 diabetes mellitus. |
| Strontium ranelate (Protos) for postmenopausal osteoporosis Professional publication - NPS RADAR - Web only item | New information relevant to this topic has become available since this RADAR review was published in November 2007. |
Complete list of all NPS RADAR content.
Find out more about NPS RADAR.
Date published: 2007-11-01 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
